Shashikant Kulkarni

MS, PhD, FACMG
Chief Scientific Officer, Emerging Business & Innovation  

Dr. Shashikant Kulkarni currently serves as Chief Scientific Officer (CSO) of Emerging Business & Innovation at Baylor Genetics. In his role as CSO, Dr. Kulkarni focuses on growth-oriented models of innovation to solve today’s burning challenges, find unmet needs, pain points, and gaps in clinical genomics. In addition, he is currently serving as a tenured Professor and Vice Chairman for Research in the Department of Molecular and Human Genetics at Baylor College of Medicine. 

Dr. Kulkarni earned his PhD from All India Institute of Medical Sciences in India. Following his PhD, Dr. Kulkarni had his fellowships at Harvard Medical School in Boston, MA, Imperial College London in the UK, and Washington University School of Medicine in St. Louis, MO. He is an American Board of Medical Genetics and Genomics board-certified medical geneticist in Clinical Molecular Genetics and Clinical Cytogenetics.  

Renowned as a pioneering leader in clinical genomics, Dr. Kulkarni has been published extensively in prestigious journals such as Cell, Nature, Nature Genetics, the New England Journal of Medicine, the Journal of American Medical Association, and more. In collaboration with the Centers for Disease Control and Prevention, Food & Drug Administration, Clinical & Laboratory Standards Institute, and National Institutes of Health, Dr. Kulkarni has played a crucial role in creating best practices for the implementation of precision genomic medicine.  

Prior to joining Baylor Genetics, Dr. Kulkarni was the Chief Managing Director of clinical genomics and molecular pathology at Washington University School of Medicine in St. Louis, MO, for over a decade.  

Dr. Kulkarni has published a book titled Clinical Genomics- A Guide to Clinical Next Generation Sequencing and is the Editor-In-Chief of the journal, Cancer Genetics (Elsevier).

Position

Professor, Vice Chair of Research, Co-Program Director
Molecular and Human Genetics
Baylor College of Medicine
Houston, TX, United States

Chief Scientific Officer
Baylor Genetics
Houston, TX, United States

Co-Program Director
American Board of Medical Genetics and Genomics (ABMGG) Laboratory Genetics

Education

Postgraduate Fellowship at Washington University School of Medicine
St. Louis, MO, United States

Postgraduate Fellowship at Harvard Medical School
Boston, MA, United States

Fellowship at Hammersmith Hospital, Imperial College
London, United Kingdom

PhD from All India Institute of Medical Sciences
New Delhi, India

Certifications

Clinical Cytogenetics
American Board of Medical Genetics and Genomics

Board Eligible in Clinical Molecular Genetics
American Board of Medical Genetics and Genomics

Publications
TBX6 null variants and a common hypomorphic allele in congenital scoliosis

Wu, N., Ming, X., Xiao, J., Wu, Z., Chen, X., Shinawi, M., Shen, Y., Yu, G., Liu, J., Xie, H., Gucev, Z.S., Liu, S., Yang, N., Al-Kateb, H., Chen, J., Zhang, J., Hauser, N., Zhang, T., Tasic, V., Liu, P., Su, X., Pan, X., Liu, C., Wang, L., Shen, J., Shen, J., Chen, Y., Zhang, T., Zhang, J., Choy, K.W., Wang, J., Wang, Q., Li, S., Zhou, W., Guo, J., Wang, Y., Zhang, C., Zhao, H., An, Y., Zhao, Y., Wang, J., Liu, Z., Zuo, Y., Tian, Y., Weng, X., Sutton, V.R., Wang, H., Ming, Y., Kulkarni, S., Zhong, T.P., Giampietro, P.F., Dunwoodie, S.L., Cheung, S.W., Zhang, X., Jin, L., Lupski, J.R., Qiu, G., and Zhang, F. (2015). TBX6 null variants and a common hypomorphic allele in congenital scoliosis. N Engl J Med 372, 341-350. PMID: 25564734

Optimizing Cancer Genome Sequencing and Analysis

Griffith M, Miller C, Griffith O, (…), Kulkarni S, Cordes M, Fronick C, Fulton R, Maher C, Ding L, Klco J, Mardis E, Ley T, Wilson R. Optimizing Cancer Genome Sequencing and Analysis. Cell Systems. 2015 September 23;1:210-323. Pubmed PMID: 26645048

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

Klco J, Miller C, Griffith M, (…), Kulkarni S, Ozenberger B, Welch J, Walter M, Graubert T, Westervelt, P, Radich J, Link D, Mardis E, DiPersio, J, Wilson R, Ley T.. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015 August 15;314:811-22. Pubmed PMID: 26305651

Good laboratory practice for clinical next-generation sequencing informatics pipelines

Gargis AS, Kalman L, Bick DP, Da Silva C, Dimmock DP, Funke BH, Gowrisankar S, Hedge MR, Kulkarni S, et. al. Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol. 2015 July;33:689-93. Pubmed PMID: 26154004

Clinical next-generation sequencing in patients with non-small cell lung cancer

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, et. al.. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015 February 15;121:631-9. Pubmed PMID: 25345567

Genetic alterations in renal cell carcinoma with rhabdoid differentiation

Perrino CM, Hucthagowder V, Evenson M, Kulkarni S, Humphrey PA. Genetic alterations in renal cell carcinoma with rhabdoid differentiation. Hum Pathol. 2015 January;46:9-16. Pubmed PMID: 25439741

Next generation sequencing in clinical diagnostics: experiences of early adopters

Lyon E, Cockerill FR 3rd, Bale SJ, Beadling C, Bry L, Hagenkord J, Kulkarni S, Press R, Palomaki GE. Next generation sequencing in clinical diagnostics: experiences of early adopters. Clin Chem. 2015 January;61:41-9. Pubmed PMID: 25421800

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

Ungewickell A, Bhanduri A, Rios E, Reuter J, Lee C, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstorng R, Weng W, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari P. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015 September;47:1056-60. Pubmed PMID: 26258847

The origin and evolution of mutations in acute myeloid leukemia

Welch JS, Ley TJ, Link DC, (…), Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, DiPersio JF, Ding L, Mardis ER, Wilson RK. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012 July 20;150:264-78. Pubmed PMID: 22817890

Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats

Stankiewicz P, Kulkarni S, Dharmadhikari AV, Sampath S, Bhatt SS, Shaikh TH, Xia Z, Pursley AN, Cooper ML, Shinawi M, Paciorkowski AR, Grange DK, Noetzel MJ, Saunders S, Simons P, Summar M, Lee B, Scaglia F, Fellmann F, Martinet D, Beckmann JS, Asamoah A,. Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats.. Hum. Mutat.. 2012 January;33(1):165-79. Pubmed PMID: 21948486

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Ding L, Ley TJ, Larson DE, (…), Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012 January 11;481:506-10. Pubmed PMID: 22237025

Shashikant Kulkarni

MS, PhD, FACMG
Chief Scientific Officer, Emerging Business & Innovation  

Dr. Shashikant Kulkarni currently serves as Chief Scientific Officer (CSO) of Emerging Business & Innovation at Baylor Genetics. In his role as CSO, Dr. Kulkarni focuses on growth-oriented models of innovation to solve today’s burning challenges, find unmet needs, pain points, and gaps in clinical genomics. In addition, he is currently serving as a tenured Professor and Vice Chairman for Research in the Department of Molecular and Human Genetics at Baylor College of Medicine. 

Dr. Kulkarni earned his PhD from All India Institute of Medical Sciences in India. Following his PhD, Dr. Kulkarni had his fellowships at Harvard Medical School in Boston, MA, Imperial College London in the UK, and Washington University School of Medicine in St. Louis, MO. He is an American Board of Medical Genetics and Genomics board-certified medical geneticist in Clinical Molecular Genetics and Clinical Cytogenetics.  

Renowned as a pioneering leader in clinical genomics, Dr. Kulkarni has been published extensively in prestigious journals such as Cell, Nature, Nature Genetics, the New England Journal of Medicine, the Journal of American Medical Association, and more. In collaboration with the Centers for Disease Control and Prevention, Food & Drug Administration, Clinical & Laboratory Standards Institute, and National Institutes of Health, Dr. Kulkarni has played a crucial role in creating best practices for the implementation of precision genomic medicine.  

Prior to joining Baylor Genetics, Dr. Kulkarni was the Chief Managing Director of clinical genomics and molecular pathology at Washington University School of Medicine in St. Louis, MO, for over a decade.  

Dr. Kulkarni has published a book titled Clinical Genomics- A Guide to Clinical Next Generation Sequencing and is the Editor-In-Chief of the journal, Cancer Genetics (Elsevier).

Position

Professor, Vice Chair of Research, Co-Program Director
Molecular and Human Genetics
Baylor College of Medicine
Houston, TX, United States

Chief Scientific Officer
Baylor Genetics
Houston, TX, United States

Co-Program Director
American Board of Medical Genetics and Genomics (ABMGG) Laboratory Genetics

Education

Postgraduate Fellowship at Washington University School of Medicine
St. Louis, MO, United States

Postgraduate Fellowship at Harvard Medical School
Boston, MA, United States

Fellowship at Hammersmith Hospital, Imperial College
London, United Kingdom

PhD from All India Institute of Medical Sciences
New Delhi, India

Certifications

Clinical Cytogenetics
American Board of Medical Genetics and Genomics

Board Eligible in Clinical Molecular Genetics
American Board of Medical Genetics and Genomics

Publications
TBX6 null variants and a common hypomorphic allele in congenital scoliosis

Wu, N., Ming, X., Xiao, J., Wu, Z., Chen, X., Shinawi, M., Shen, Y., Yu, G., Liu, J., Xie, H., Gucev, Z.S., Liu, S., Yang, N., Al-Kateb, H., Chen, J., Zhang, J., Hauser, N., Zhang, T., Tasic, V., Liu, P., Su, X., Pan, X., Liu, C., Wang, L., Shen, J., Shen, J., Chen, Y., Zhang, T., Zhang, J., Choy, K.W., Wang, J., Wang, Q., Li, S., Zhou, W., Guo, J., Wang, Y., Zhang, C., Zhao, H., An, Y., Zhao, Y., Wang, J., Liu, Z., Zuo, Y., Tian, Y., Weng, X., Sutton, V.R., Wang, H., Ming, Y., Kulkarni, S., Zhong, T.P., Giampietro, P.F., Dunwoodie, S.L., Cheung, S.W., Zhang, X., Jin, L., Lupski, J.R., Qiu, G., and Zhang, F. (2015). TBX6 null variants and a common hypomorphic allele in congenital scoliosis. N Engl J Med 372, 341-350. PMID: 25564734

Optimizing Cancer Genome Sequencing and Analysis

Griffith M, Miller C, Griffith O, (…), Kulkarni S, Cordes M, Fronick C, Fulton R, Maher C, Ding L, Klco J, Mardis E, Ley T, Wilson R. Optimizing Cancer Genome Sequencing and Analysis. Cell Systems. 2015 September 23;1:210-323. Pubmed PMID: 26645048

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia

Klco J, Miller C, Griffith M, (…), Kulkarni S, Ozenberger B, Welch J, Walter M, Graubert T, Westervelt, P, Radich J, Link D, Mardis E, DiPersio, J, Wilson R, Ley T.. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA. 2015 August 15;314:811-22. Pubmed PMID: 26305651

Good laboratory practice for clinical next-generation sequencing informatics pipelines

Gargis AS, Kalman L, Bick DP, Da Silva C, Dimmock DP, Funke BH, Gowrisankar S, Hedge MR, Kulkarni S, et. al. Good laboratory practice for clinical next-generation sequencing informatics pipelines. Nat Biotechnol. 2015 July;33:689-93. Pubmed PMID: 26154004

Clinical next-generation sequencing in patients with non-small cell lung cancer

Hagemann IS, Devarakonda S, Lockwood CM, Spencer DH, Guebert K, Bredemeyer AJ, Al-Kateb H, Nguyen TT, Duncavage EJ, Cottrell CE, Kulkarni S, et. al.. Clinical next-generation sequencing in patients with non-small cell lung cancer. Cancer. 2015 February 15;121:631-9. Pubmed PMID: 25345567

Genetic alterations in renal cell carcinoma with rhabdoid differentiation

Perrino CM, Hucthagowder V, Evenson M, Kulkarni S, Humphrey PA. Genetic alterations in renal cell carcinoma with rhabdoid differentiation. Hum Pathol. 2015 January;46:9-16. Pubmed PMID: 25439741

Next generation sequencing in clinical diagnostics: experiences of early adopters

Lyon E, Cockerill FR 3rd, Bale SJ, Beadling C, Bry L, Hagenkord J, Kulkarni S, Press R, Palomaki GE. Next generation sequencing in clinical diagnostics: experiences of early adopters. Clin Chem. 2015 January;61:41-9. Pubmed PMID: 25421800

Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2

Ungewickell A, Bhanduri A, Rios E, Reuter J, Lee C, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstorng R, Weng W, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari P. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015 September;47:1056-60. Pubmed PMID: 26258847

The origin and evolution of mutations in acute myeloid leukemia

Welch JS, Ley TJ, Link DC, (…), Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, DiPersio JF, Ding L, Mardis ER, Wilson RK. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012 July 20;150:264-78. Pubmed PMID: 22817890

Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats

Stankiewicz P, Kulkarni S, Dharmadhikari AV, Sampath S, Bhatt SS, Shaikh TH, Xia Z, Pursley AN, Cooper ML, Shinawi M, Paciorkowski AR, Grange DK, Noetzel MJ, Saunders S, Simons P, Summar M, Lee B, Scaglia F, Fellmann F, Martinet D, Beckmann JS, Asamoah A,. Recurrent deletions and reciprocal duplications of 10q11.21q11.23 including CHAT and SLC18A3 are likely mediated by complex low-copy repeats.. Hum. Mutat.. 2012 January;33(1):165-79. Pubmed PMID: 21948486

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing

Ding L, Ley TJ, Larson DE, (…), Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012 January 11;481:506-10. Pubmed PMID: 22237025

Menu